{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:15:42Z","timestamp":1790874942004,"version":"4.1.0"},"reference-count":46,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,11,28]],"date-time":"2006-11-28T00:00:00Z","timestamp":1164672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2007,1,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We sought to review the long\u2010term tolerability of tetrabenazine (TBZ) and seek determinants of tolerability in the treatment of hyperkinetic movement disorders. A retrospective chart review was performed on patients treated with TBZ between 1997 and 2004. Efficacy of TBZ was assessed by a 1\u2010 to 5\u2010point response scale (1 = marked reduction in abnormal movements, 5 = worsening). All adverse events (AEs) were captured according to their relationship with study drug. A total of 448 patients (42% male) were treated for a variety of hyperkinesias, including tardive dyskinesia (n = 149), dystonia (n = 132), chorea (n = 98), tics (n = 92), and myoclonus (n = 19). The mean age at onset of the movement disorder was 43.0 \u00b1 24.2 years, with TBZ starting at a mean age of 50.0 \u00b1 22.3 years. Patients remained on treatment for a mean of 2.3 \u00b1 3.4 years. An efficacy response rating of 1 or 2 was sustained in the majority of patients between the first and last visit. Common AEs included drowsiness (25.0%), Parkinsonism (15.4%), depression (7.6%), and akathisia (7.6%). Comparison of log\u2010likelihood ratios revealed that age was a reliable predictor of Parkinsonism (<jats:italic>P<\/jats:italic> &lt; 0.0001). TBZ is a safe and effective drug for the long\u2010term treatment of hyperkinetic movement disorders. \u00a9 2006 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.21222","type":"journal-article","created":{"date-parts":[[2006,11,28]],"date-time":"2006-11-28T17:23:22Z","timestamp":1164734602000},"page":"193-197","source":"Crossref","is-referenced-by-count":163,"title":["Long\u2010term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders"],"prefix":"10.1002","volume":"22","author":[{"given":"Christopher","family":"Kenney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,11,28]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0022-3565(25)25665-8","article-title":"Biochemical and pharmacological studies of RO 1\u20109569 (tetrabenazine), a nonindole tranquilizing agent with reserpine\u2010like effects","volume":"127","author":"Quinn GP","year":"1959","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(84)90562-4"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.1986.tb04506.x"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410120308"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0022-3565(25)33621-9","article-title":"Tetrabenazine, an amine\u2010depleting drug, also blocks dopamine receptors in rat brain","volume":"225","author":"Reches A","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0074-7742(08)60024-0"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.2.358"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200211000-00003"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000136892.24629.96"},{"key":"e_1_2_6_11_2","first-page":"1244","article-title":"A randomized, double\u2010blind, placebo\u2010controlled, staggered withdrawal study in patients with Huntington's disease treated with tetrabenazine","volume":"20","author":"Frank S","year":"2005","journal-title":"Mov Disord"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000198586.85250.13"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.6.1.7"},{"key":"e_1_2_6_14_2","article-title":"Short\u2010term effects of tetrabenazine on chorea associated with Huntington disease","author":"Kenney C","year":"2006","journal-title":"Mov Disord"},{"key":"e_1_2_6_15_2","first-page":"19","article-title":"A therapeutic approach to tardive dyskinesia","volume":"46","author":"Fahn S","year":"1985","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_6_16_2","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1176\/ajp.156.8.1279","article-title":"Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol","volume":"156","author":"Ondo WG","year":"1999","journal-title":"Am J Psychiatry"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-000-0003-4"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.5.688"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100038087"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161150-00005"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199506000-00001"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674370505000907"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674370505001110"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2005.10.014"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113284"},{"key":"e_1_2_6_26_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1176\/ajp.130.4.479","article-title":"Long\u2010term treatment of tardive dyskinesia with haloperidol and tetrabenazine","volume":"130","author":"Kazamatsuri H","year":"1973","journal-title":"Am J Psychiatry"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1983.tb04816.x"},{"key":"e_1_2_6_28_2","article-title":"Is history of depression a contraindication to treatment with tetrabenazine","author":"Kenney C","year":"2006","journal-title":"Mov Disord"},{"key":"e_1_2_6_29_2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1742-1241.1972.tb04414.x","article-title":"Self\u2010poisoning with tetrabenazine","volume":"26","author":"Kidd DW","year":"1972","journal-title":"Br J Clin Pract"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001340050583"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.31.8.1022"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199202000-00009"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110118"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870120219"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410170217"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1177\/003693307201701105"},{"key":"e_1_2_6_37_2","first-page":"79","article-title":"Huntington's disease (HD): effect of tetrabenazine and antipsychotic drugs on motoric features","volume":"31","author":"Shoulson I","year":"1981","journal-title":"Neurology"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1976.tb140870.x"},{"key":"e_1_2_6_39_2","first-page":"282","article-title":"Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements","volume":"4","author":"Gimenez\u2010Roldan S","year":"1989","journal-title":"Neurologia"},{"issue":"9","key":"e_1_2_6_40_2","first-page":"S73","article-title":"Tetrabenazine: effective treatment for tardive dyskinesia","volume":"19","author":"Jankovic J","year":"2004","journal-title":"Mov Disord"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.1.18"},{"key":"e_1_2_6_42_2","first-page":"647","article-title":"Infliximab: additional safety data from an open label study","volume":"29","author":"Daniel CL","year":"2002","journal-title":"J Rheumatol"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.3109\/08037059209077502"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410110108"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.31.8.1051"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.35.2.186"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(74)92338-1"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.21222","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.21222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:35:54Z","timestamp":1760963754000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.21222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,28]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007,1,15]]}},"alternative-id":["10.1002\/mds.21222"],"URL":"https:\/\/doi.org\/10.1002\/mds.21222","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,28]]}}}